Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pTVG-HP and Nivolumab in Non-Metastatic, PSA-Recurrent Prostate Cancer
NCT03600350Phase 2Active, not recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2018
- Primary completion
- Nov 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pTVG-HP plasmid DNA vaccine in prostate cancer (PCa), sponsored by University of Wisconsin–Madison. Started Sep 2018; status: active, not recruiting.
02
Drugs
pTVG-HP plasmid DNA vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03600350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600350.